Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
Clinical trial NCT03839446 · COMPLETED
Trial details
- NCT number
- NCT03839446
- Sponsor
- Robert Redner, MD
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2019-02-28
- Primary completion
- 2023-02-02
- Enrollment
- 16
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.